With the introduction of molecular-targeted drugs such as anti-EGFR monoclonal antibody therapies and angiogenesis inhibitors, treatment options for patients with metastatic colorectal cancer have changed considerably. The gene discussed is EGFR; the disease is metastatic colorectal cancer.